eigerbioadmin

»eigerbioadmin

About eigerbioadmin

This author has not yet filled in any details.
So far eigerbioadmin has created 95 blog entries.
16 01, 2018

Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint

2018-01-16T13:17:12+00:00

Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint - End of Phase 2 Meeting Scheduled for HDV in February 2018 - Phase 2 Readouts for PBH and Lymphedema in Second Half 2018 PALO ALTO, Calif., January 16, 2018 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development [...]

Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint 2018-01-16T13:17:12+00:00
8 01, 2018

Eiger BioPharmaceuticals Announces Appointment of Commercial Operations Industry Veteran Eldon Mayer to its Board of Directors

2018-01-08T14:36:31+00:00

Eiger BioPharmaceuticals Announces Appointment of Commercial Operations Industry Veteran Eldon Mayer to its Board of Directors PALO ALTO, Calif., January 8, 2018 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of Eldon Mayer to its Board of Directors.  Mr. Mayer is a pharmaceutical [...]

Eiger BioPharmaceuticals Announces Appointment of Commercial Operations Industry Veteran Eldon Mayer to its Board of Directors 2018-01-08T14:36:31+00:00
4 01, 2018

Eiger BioPharmaceuticals Completes Enrollment of Phase 2 ULTRA Study of Ubenimex in Primary and Secondary Lymphedema Patients

2018-01-04T15:07:20+00:00

Eiger BioPharmaceuticals Completes Enrollment of Phase 2 ULTRA Study of Ubenimex in Primary and Secondary Lymphedema Patients - ULTRA Study Data Expected in Second Half 2018 PALO ALTO, Calif., January 4, 2018 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion of enrollment of the [...]

Eiger BioPharmaceuticals Completes Enrollment of Phase 2 ULTRA Study of Ubenimex in Primary and Secondary Lymphedema Patients 2018-01-04T15:07:20+00:00
3 01, 2018

Eiger BioPharmaceuticals Appoints David Apelian, MD, PhD, MBA Chief Operating Officer and Executive Medical Officer

2018-01-03T15:51:50+00:00

Eiger BioPharmaceuticals Appoints David Apelian, MD, PhD, MBA Chief Operating Officer and Executive Medical Officer PALO ALTO, Calif., January 3, 2018 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of David Apelian, MD, PhD, MBA as Chief Operating Officer and Executive Medical Officer. [...]

Eiger BioPharmaceuticals Appoints David Apelian, MD, PhD, MBA Chief Operating Officer and Executive Medical Officer 2018-01-03T15:51:50+00:00
2 01, 2018

Eiger BioPharmaceuticals to Present at Biotech ShowcaseTM 2018

2018-01-03T15:43:08+00:00

Eiger BioPharmaceuticals to Present at Biotech Showcase™ 2018 PALO ALTO, Calif. – January 2, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory, President and CEO, will present a corporate update at Biotech Showcase™ 2018 on January 8th at 2:00 pm [...]

Eiger BioPharmaceuticals to Present at Biotech ShowcaseTM 2018 2018-01-03T15:43:08+00:00
13 11, 2017

Eiger BioPharmaceuticals to Present at Jefferies 2017 Healthcare Conference

2017-11-13T13:13:47+00:00

Eiger BioPharmaceuticals to Present at Jefferies 2017 Healthcare Conference PALO ALTO, Calif. – November 13, 2017 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate update at Jefferies 2017 Healthcare Conference on Thursday, November [...]

Eiger BioPharmaceuticals to Present at Jefferies 2017 Healthcare Conference 2017-11-13T13:13:47+00:00
9 11, 2017

Eiger BioPharmaceuticals Reports Third Quarter 2017 Financial Results

2017-11-09T13:15:05+00:00

Eiger BioPharmaceuticals Reports Third Quarter 2017 Financial Results Clinical Results Planned in Each of Four Orphan Disease Programs by 4Q 2018 Cash Runway Extends Through Mid-2019 PALO ALTO, Calif., November 9, 2017 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today financial results for [...]

Eiger BioPharmaceuticals Reports Third Quarter 2017 Financial Results 2017-11-09T13:15:05+00:00
6 11, 2017

Eiger BioPharmaceuticals to Participate in Upcoming Investor Conferences

2017-11-06T13:14:37+00:00

Eiger BioPharmaceuticals to Participate in Upcoming Investor Conferences PALO ALTO, Calif. – November 6, 2017 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory, President and CEO of Eiger, will participate and present in three upcoming investor conferences. Jefferies 2017 London Healthcare Conference, [...]

Eiger BioPharmaceuticals to Participate in Upcoming Investor Conferences 2017-11-06T13:14:37+00:00
31 10, 2017

Eiger BioPharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise In Full of Underwriter’s Option to Purchase Additional Shares

2017-10-31T21:11:35+00:00

Eiger BioPharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise In Full of Underwriter’s Option to Purchase Additional Shares PALO ALTO, Calif., October 31, 2017 /PR Newswire/ — Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced the closing [...]

Eiger BioPharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise In Full of Underwriter’s Option to Purchase Additional Shares 2017-10-31T21:11:35+00:00
27 10, 2017

Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock

2017-10-27T15:17:14+00:00

Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock PALO ALTO, Calif., October 27, 2017 /PR Newswire/ — Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced the pricing of its underwritten public offering of 1,854,749 shares of its common [...]

Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock 2017-10-27T15:17:14+00:00